Effects of Long-Acting Beraprost Sodium (TRK-100STP) in Japanese Patients With Pulmonary Arterial Hypertension
-
- Kunieda Takeyoshi
- Department of Cardiovascular Medicine, Kaken Hospital, Clinical Medical Research Center, International University of Health and Welfare
-
- Nakanishi Norifumi
- Division of Cardiology, Department of Medicine, National Cardiovascular Center
-
- Matsubara Hiromi
- Division of Cardiology, National Hospital Organization Okayama Medical Center
-
- Ohe Tohru
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
-
- Okano Yoshiaki
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine
-
- Kondo Hirobumi
- Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine
-
- Nishimura Masaharu
- First Department of Medicine, Hokkaido University Graduate School of Medicine
-
- Shirato Kunio
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
-
- Tanabe Nobuhiro
- Department of Respirology, Chiba University Graduate School of Medicine
-
- Homma Satoshi
- Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Science, University of Tsukuba
-
- Yoshida Shunji
- Division of Rheumatology and Infectious Diseases, Department of Internal Medicine, Fujita Health University School of Medicine
-
- Inokuma Shigeko
- Department of Allergy and Immunological Diseases, Tokyo Metropolitan Komagome Hospital
-
- Kodama Makoto
- First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Koike Takao
- Second Department of Medicine, Hokkaido University Graduate School of Medicine
-
- Hishida Hitoshi
- Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine
この論文をさがす
抄録
The long-acting beraprost preparation TRK-100STP is formulated to provide sustained release of an orally active prostacyclin derivative to maintain the optimal plasma concentration for a longer period of time compared with the currently used conventional beraprost sodium. In the present study, we evaluated the efficacy of this newly developed formulation for pulmonary arterial hypertension (PAH).<br>An open-label, 12-week multicenter clinical trial was performed in 46 patients with PAH. They were initially treated with 120 μg of TRK-100STP divided into 60 μg twice daily, followed by a stepwise increase to 360 μg given as 180 μg twice daily. The 6-minute walking distance showed a significant increase by 33.4 ± 66.0 m (95% confidence interval [CI], 13.4 to 53.5) from the baseline measurement. Mean pulmonary artery pressure, total pulmonary vascular resistance, and pulmonary vascular resistance decreased by –2.8 ± 5.5 mmHg (95% CI, –4.6 to –1.0), by –0.92 ± 2.63 mmHg•L–1•min (95% CI, –1.78 to –0.05), and by –0.89 ± 2.81 mmHg•L–1•min (95% CI, –1.84 to 0.06), respectively, from the baseline measurements. A higher efficacy was observed in patients with a maximum tolerated dose of 360 μg daily than those of 240 μg daily or less.<br>Treatment with TRK-100STP for a 12-week period improved the exercise capacity, mean pulmonary artery pressure, and total pulmonary vascular resistance. TRK-100STP was effective for Japanese patients with PAH.
収録刊行物
-
- International Heart Journal
-
International Heart Journal 50 (4), 513-529, 2009
一般社団法人 インターナショナル・ハート・ジャーナル刊行会